Categories
Change Password!
Reset Password!
Compared to urea 10%, the emollient “plus” shows superior clinical and skin barrier outcomes in atopic dermatitis patients.
A new clinical trial from Indonesia suggests that a next-generation “emollient plus” infused with Vitreoscilla filiformis biomass may offer a more effective strategy for managing mild-to-moderate atopic dermatitis (AD) than the traditionally used 10% urea moisturizer. By targeting microbiome balance and skin barrier repair, the novel formulation delivered broader symptom relief and improved skin health over a 12-week period.
The study enrolled 60 individuals with mild-to-moderate AD, randomly assigning them to receive either the microbiome-friendly emollient or a standard urea-based moisturizer twice daily. Researchers monitored both groups at weeks 0, 4, 8, and 12, evaluating clinical outcomes such as eczema severity (SCORing Atopic Dermatitis [SCORAD] and Eczema Area and Severity Index [EASI]), itch intensity (PVAS), skin quality (transepidermal water loss [TEWL], hydration, pH), and overall life quality (Dermatology Life Quality Index [DLQI]).
Notably, the emollient plus outperformed its counterpart in several key areas. By week 4, significant improvements were seen in TEWL and skin pH, with sustained benefits continuing through week 12. SCORAD and hydration levels were markedly better in the emollient group by weeks 8 and 12, while eczema severity, itch relief, and quality of life showed significant gains at the final assessment point. Both products were well-tolerated.
Researchers highlight that while 10% urea remains a standard option in AD care, formulations enriched with bacterial lysate such as Aqua Posae Filiformis offer a modern, microbiome-centered alternative—suitable as a stand-alone treatment in milder cases or as an add-on to systemic therapy in more severe disease. The findings support a growing shift towards barrier-restoring, microbiota-supportive skincare in chronic dermatologic ailments.
Journal of Cosmetic Dermatology
Effectiveness and Tolerability of an Emollient “Plus” Compared to Urea 10% in Patients With Mild‐to‐Moderate Atopic Dermatitis
Cita Rosita Sigit Prakoeswa et al.
Comments (0)